Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
In: Archives of Dermatological Research, Jg. 316 (2024-09-01), Heft 7, S. 1-11
Online
academicJournal
Zugriff:
Secukinumab is a fully human IgG1 antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A. Secukinumab is an effective and well-tolerated treatment for plaque psoriasis. There is a limited real-word evidence for dose optimisation of secukinumab based on clinical response. PURE is a multi-national, prospective, observational study in patients with moderate to severe chronic plaque psoriasis in Canada and Latin America, assessing the real-world safety and effectiveness of secukinumab and other indicated therapies. The aim of the current snapshot analysis was to evaluate the effectiveness and safety of on-label dose and updosed secukinumab in patients with plaque psoriasis enrolled in the PURE study. At the time of analysis, 676 patients received secukinumab, of which 84.6% (n = 572) remained on the on-label dose, while 15.4% (n = 104) were updosed. With on-label secukinumab, the absolute Psoriasis Area and Severity Index (PASI) score was reduced from 13.6 at baseline to 1.2 over 36 months, with treatment persistence of 73% at 40 months. At Month 36, 73.2% of the patients receiving on-label secukinumab achieved Investigator's Global Assessment (IGA) 0/1. With updosed secukinumab (300 mg every 2 weeks, 300 mg every 3 weeks, 450 mg every 4 weeks, or 450 mg every 3 weeks), 57.9% of the patients showed improvement in the absolute PASI score at the first visit after updosing, with treatment persistence of 50% at 12 months after updosing. At Month 15, 40% of patients receiving updosed secukinumab achieved IGA 0/1. Patients with previous biologic exposure (odds ratio [OR]: 3.25; 95% confidence interval [CI]: 2.03, 5.18, p < 0.0001) were more likely to be updosed while those with a body weight < 90 kg (OR: 0.49; 95% CI [0.31, 0.77], p = 0.0019) were less likely to be updosed. Previous biologic exposure (HR [hazard ratio]: 1.47; 95% CI [1.24, 1.75], p < 0.0001) and current biologic exposure (secukinumab vs. other indicated therapies: HR 0.57; 95% CI [0.43, 0.75], p = 0.0001) were significantly associated with time to secukinumab updosing. No new or unexpected safety signals were observed with updosed secukinumab. Secukinumab updosing was efficacious and well-tolerated in patients with psoriasis who failed to respond to the approved on-label regimen, suggesting that updosing may be a useful therapeutic option for approved dose non-responders. [ABSTRACT FROM AUTHOR]
Titel: |
Effectiveness and safety of secukinumab updosing in patients with moderate to severe plaque psoriasis: data from the PURE registry.
|
---|---|
Autor/in / Beteiligte Person: | Papp, Kim A. ; Gooderham, Melinda ; Lynde, Charles ; Brassard, Danielle ; Al-Mohammedi, Faisal ; Prajapati, Vimal H. ; Delorme, Isabelle ; Albrecht, Lorne ; Haydey, Richard ; Alam, Maryam Shayesteh ; Beecker, Jennifer ; Siddha, Sanjay ; Maguin, Marie ; Farag, Mahmoud S. ; Vieira, Antonio ; Rihakova, Lenka ; Langley, Richard G. |
Link: | |
Zeitschrift: | Archives of Dermatological Research, Jg. 316 (2024-09-01), Heft 7, S. 1-11 |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 0340-3696 (print) |
DOI: | 10.1007/s00403-024-03122-w |
Schlagwort: |
|
Sonstiges: |
|